Russia’s Sputnik vaccine shows 91.6% efficacy in clinical trials

World

Russia’s Sputnik vaccine shows 91.6% efficacy in clinical trials

Lancet peer review confirms performance of country’s flagship two-shot jab

Donato Paolo Mancini and Max Seddon

Russia’s flagship two-shot Sputnik V vaccine has shown 91.6% efficacy against symptomatic Covid-19 in clinical trials, a Lancet peer review has confirmed, bringing the global total of vaccines whose efficacy is confirmed to be higher than 90% to three.

The results from an interim analysis, now confirmed by peer review, also showed the jab provided full protection against moderate or severe cases of Covid-19.

Alexander Gintsburg, director of Russia’s Gamaleya Institute, the state-run virology research centre that developed the jab, said the results were a “monumental achievement” and “a great success in the battle against the global Covid-19 pandemic”...

This article is reserved for Sunday Times Daily subscribers.
A subscription gives you full digital access to all Sunday Times Daily content.

Sunday Times Daily

Already subscribed? Simply sign in below.

Questions or problems?
Email helpdesk@timeslive.co.za or call 0860 52 52 00.

Previous Article